NASDAQ:NXTC NextCure Q3 2024 Earnings Report $1.97 -0.03 (-1.50%) Closing price 04:00 PM EasternExtended Trading$1.97 +0.00 (+0.20%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast NextCure EPS ResultsActual EPS-$4.92Consensus EPS -$4.20Beat/MissMissed by -$0.72One Year Ago EPSN/ANextCure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANextCure Announcement DetailsQuarterQ3 2024Date11/7/2024TimeAfter Market ClosesConference Call DateThursday, November 7, 2024Conference Call Time3:00PM ETUpcoming EarningsNextCure's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NextCure Earnings HeadlinesNextCure, Inc. (NASDAQ:NXTC) Short Interest Up 228.4% in JuneJune 30, 2026 | americanbankingnews.comNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersJune 4, 2026 | globenewswire.comIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history. George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline.July 10 at 1:00 AM | Eagle Publishing (Ad)NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma TranscriptJune 2, 2026 | seekingalpha.comNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026June 1, 2026 | globenewswire.comNextCure (NXTC) Stock Forecast & Price TargetMay 25, 2026 | investing.comSee More NextCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email. Email Address About NextCureNextCure (NASDAQ:NXTC) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development. The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation. Lead programs such as NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint, and NX-0255, a monoclonal antibody directed against KIR3DL2, are being developed for solid tumors and hematologic malignancies. NextCure is also advancing NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, into studies for B-cell malignancies. Strategic partnerships with global pharmaceutical companies support NextCure’s efforts to expand its research capabilities and accelerate clinical programs across oncology and immunology indications. Founded in 2013 and headquartered in Beltsville, Maryland, NextCure operates state‐of‐the‐art research and development facilities in the greater Washington, D.C. area. The company conducts clinical trials across North America and Europe, collaborating with leading academic institutions and healthcare centers. By combining novel target discovery with rigorous translational and clinical research, NextCure seeks to bring new immunotherapeutic options to patients worldwide.View NextCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real ProfitLockheed Martin Secures the Ultimate Defense MoatWhy Levi's Digital Strategy Is Paying Off in a Big WayConstellation Brands: Beer Growth and Buybacks Mask Stock's SlumpWhy Exxon Could Be the Market's Next Big Comeback Stock Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
